Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion

Published: 01 April 2021

  • Views:

    Views Icon 4786
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 3 | Session 1 of 1
    Derek Connolly
    Derek Connolly
    Up Next
  • episode_image
    Part 4 | Session 1 Su Down
    Su Down

Overview

This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.

 

Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.

Key Learning Objectives

  • Describe how and when to prescribe SGLT2 inhibitors
  • Identify patients who are suitable for SGLT2 inhibitors
  • Provide appropriate patient education and advice when initiating SGLT2 inhibitors
  • Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety

Faculty

  • Dr Jas Gill - GP with Special Interest in Cardiology
  • Dr Andrew Frankel - Consultant Nephrologist
  • Dr Derek Connolly - Consultant Interventional Cardiologist
  • Su Down - Nurse Consultant in Diabetes

More from this programme

Part 1

Welcome and Introductions

Part 2

SGLT2 inhibitors: Initiation in Diabetic Kidney Disease

Part 3

SGLT2 Inhibitors in Heart Failure

Part 4

Practical aspects of initiating in Diabetes

1 session
Su Down Watch now

Part 5

Practical Prescribing

1 session
Jas Gill Watch now

Faculty Biographies

Derek Connolly

Derek Connolly

Consultant Interventional Cardiologist

Professor Derek Connolly is a Consultant Interventional Cardiologist and the Director of Research and Development at Birmingham City Hospital. He is an Honorary Senior Clinical Lecturer at the Institute of Cardiovascular Sciences, University of Birmingham, UK.

He trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. He has a first-class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His PhD in molecular cardiology is from the University of Cambridge. He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. He developed one of the UK's first primary angioplasty programmes and one of the UK's largest cardiac CT programmes.

View full profile